{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:38:44Z","timestamp":1792089524453,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-99558-9","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T15:56:25Z","timestamp":1746201385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mir-494-3p enhances aggressive phenotype of non-small cell lung cancer cells by regulating SET\/I2PP2A"],"prefix":"10.1038","volume":"15","author":[{"given":"Yuwen","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Kajino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"99558_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"99558_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553, 446\u2013454. https:\/\/doi.org\/10.1038\/nature25183 (2018).","journal-title":"Nature"},{"key":"99558_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F. & Heist, R. S. Lung cancer. Lancet 398, 535\u2013554. https:\/\/doi.org\/10.1016\/S0140-6736(21)00312-3 (2021).","journal-title":"Lancet"},{"key":"99558_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw, P. et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 11, 39\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2015.09.009 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"99558_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrc3932","volume":"15","author":"S Lin","year":"2015","unstructured":"Lin, S. & Gregory, R. I. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer 15, 321\u2013333. https:\/\/doi.org\/10.1038\/nrc3932 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"99558_CR6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.18632\/oncotarget.22633","volume":"9","author":"Z Xiang","year":"2018","unstructured":"Xiang, Z. et al. Prognostic and clinicopathological significance of microRNA-494 overexpression in cancers: A meta-analysis. Oncotarget 9, 1279\u20131290. https:\/\/doi.org\/10.18632\/oncotarget.22633 (2018).","journal-title":"Oncotarget"},{"key":"99558_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.lfs.2009.12.002","volume":"86","author":"L Liu","year":"2010","unstructured":"Liu, L., Jiang, Y., Zhang, H., Greenlee, A. R. & Han, Z. Overexpressed miR-494 down-regulates PTEN gene expression in cells transformed by anti-benzo(a)pyrene-trans-7,8-dihydrodiol-9,10-epoxide. Life Sci. 86, 192\u2013198. https:\/\/doi.org\/10.1016\/j.lfs.2009.12.002 (2010).","journal-title":"Life Sci."},{"key":"99558_CR8","doi-asserted-by":"publisher","first-page":"16570","DOI":"10.1073\/pnas.1207917109","volume":"109","author":"G Romano","year":"2012","unstructured":"Romano, G. et al. MiR-494 is regulated by ERK1\/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc. Natl. Acad. Sci. U. S. A. 109, 16570\u201316575. https:\/\/doi.org\/10.1073\/pnas.1207917109 (2012).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"99558_CR9","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1038\/s41598-019-39453-2","volume":"9","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. MiR-494 acts as a tumor promoter by targeting CASP2 in non-small cell lung cancer. Sci. Rep. 9, 3008. https:\/\/doi.org\/10.1038\/s41598-019-39453-2 (2019).","journal-title":"Sci. Rep."},{"key":"99558_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3892\/etm.2023.11941","volume":"25","author":"X Gao","year":"2023","unstructured":"Gao, X. et al. Downregulation of microRNA-494 inhibits cell proliferation in lung squamous cell carcinoma via the induction of PUMA-alpha-mediated apoptosis. Exp. Ther. Med. 25, 242. https:\/\/doi.org\/10.3892\/etm.2023.11941 (2023).","journal-title":"Exp. Ther. Med."},{"key":"99558_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.cell.2020.06.013","volume":"182","author":"MA Gillette","year":"2020","unstructured":"Gillette, M. A. et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell 182, 200-225 e235. https:\/\/doi.org\/10.1016\/j.cell.2020.06.013 (2020).","journal-title":"Cell"},{"key":"99558_CR12","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1016\/j.cell.2021.07.016","volume":"184","author":"S Satpathy","year":"2021","unstructured":"Satpathy, S. et al. A proteogenomic portrait of lung squamous cell carcinoma. Cell 184, 4348-4371 e4340. https:\/\/doi.org\/10.1016\/j.cell.2021.07.016 (2021).","journal-title":"Cell"},{"key":"99558_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543\u2013550. https:\/\/doi.org\/10.1038\/nature13385 (2014).","journal-title":"Nature"},{"key":"99558_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","volume":"489","author":"Cancer Genome Atlas Research N","year":"2012","unstructured":"Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519\u2013525. https:\/\/doi.org\/10.1038\/nature11404 (2012).","journal-title":"Nature"},{"key":"99558_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jnci\/djab183","volume":"114","author":"I Tanaka","year":"2022","unstructured":"Tanaka, I. et al. SRGN-triggered aggressive and immunosuppressive phenotype in a subset of TTF-1-negative lung adenocarcinomas. J. Natl. Cancer Inst. 114, 290\u2013301. https:\/\/doi.org\/10.1093\/jnci\/djab183 (2022).","journal-title":"J. Natl. Cancer Inst."},{"key":"99558_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav1741","author":"SE McGeary","year":"2019","unstructured":"McGeary, S. E. et al. The biochemical basis of microRNA targeting efficacy. Science https:\/\/doi.org\/10.1126\/science.aav1741 (2019).","journal-title":"Science"},{"key":"99558_CR17","doi-asserted-by":"publisher","first-page":"D127","DOI":"10.1093\/nar\/gkz757","volume":"48","author":"Y Chen","year":"2020","unstructured":"Chen, Y. & Wang, X. miRDB: An online database for prediction of functional microRNA targets. Nucleic Acids Res. 48, D127\u2013D131. https:\/\/doi.org\/10.1093\/nar\/gkz757 (2020).","journal-title":"Nucleic Acids Res."},{"key":"99558_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206239","volume":"13","author":"C Sticht","year":"2018","unstructured":"Sticht, C., De La Torre, C., Parveen, A. & Gretz, N. miRWalk: An online resource for prediction of microRNA binding sites. PLoS ONE 13, e0206239. https:\/\/doi.org\/10.1371\/journal.pone.0206239 (2018).","journal-title":"PLoS ONE"},{"key":"99558_CR19","doi-asserted-by":"publisher","first-page":"W148","DOI":"10.1093\/nar\/gkad283","volume":"51","author":"S Tastsoglou","year":"2023","unstructured":"Tastsoglou, S. et al. DIANA-microT 2023: Including predicted targets of virally encoded miRNAs. Nucleic Acids Res. 51, W148\u2013W153. https:\/\/doi.org\/10.1093\/nar\/gkad283 (2023).","journal-title":"Nucleic Acids Res."},{"key":"99558_CR20","doi-asserted-by":"publisher","first-page":"7231","DOI":"10.18632\/oncotarget.13933","volume":"8","author":"A Faversani","year":"2017","unstructured":"Faversani, A. et al. miR-494-3p is a novel tumor driver of lung carcinogenesis. Oncotarget 8, 7231\u20137247. https:\/\/doi.org\/10.18632\/oncotarget.13933 (2017).","journal-title":"Oncotarget"},{"key":"99558_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10456-015-9474-5","volume":"18","author":"G Mao","year":"2015","unstructured":"Mao, G. et al. Tumor-derived microRNA-494 promotes angiogenesis in non-small cell lung cancer. Angiogenesis 18, 373\u2013382. https:\/\/doi.org\/10.1007\/s10456-015-9474-5 (2015).","journal-title":"Angiogenesis"},{"key":"99558_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.663183","volume":"11","author":"C Shao","year":"2021","unstructured":"Shao, C. et al. Targeting c-Jun in A549 cancer cells exhibits antiangiogenic activity in vitro and in vivo through exosome\/miRNA-494-3p\/PTEN signal pathway. Front. Oncol. 11, 663183. https:\/\/doi.org\/10.3389\/fonc.2021.663183 (2021).","journal-title":"Front. Oncol."},{"key":"99558_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41419-022-04594-2","volume":"13","author":"O Kim","year":"2022","unstructured":"Kim, O., Hwangbo, C., Tran, P. T. & Lee, J. H. Syntenin-1-mediated small extracellular vesicles promotes cell growth, migration, and angiogenesis by increasing onco-miRNAs secretion in lung cancer cells. Cell Death Dis. 13, 122. https:\/\/doi.org\/10.1038\/s41419-022-04594-2 (2022).","journal-title":"Cell Death Dis."},{"key":"99558_CR24","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.4049\/jimmunol.1103505","volume":"188","author":"Y Liu","year":"2012","unstructured":"Liu, Y. et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J. Immunol. 188, 5500\u20135510. https:\/\/doi.org\/10.4049\/jimmunol.1103505 (2012).","journal-title":"J. Immunol."},{"key":"99558_CR25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.21037\/tlcr-21-955","volume":"11","author":"D Kazmierczak","year":"2022","unstructured":"Kazmierczak, D. et al. Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer. Transl Lung Cancer Res 11, 722\u2013734. https:\/\/doi.org\/10.21037\/tlcr-21-955 (2022).","journal-title":"Transl Lung Cancer Res"},{"key":"99558_CR26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3233\/CBM-170337","volume":"21","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients. Cancer Biomark. 21, 763\u2013768. https:\/\/doi.org\/10.3233\/CBM-170337 (2018).","journal-title":"Cancer Biomark."},{"key":"99558_CR27","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20221280","author":"A Di Mambro","year":"2022","unstructured":"Di Mambro, A. & Esposito, M. T. Thirty years of SET\/TAF1beta\/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer\u2019s disease. Biosci. Rep. https:\/\/doi.org\/10.1042\/BSR20221280 (2022)."},{"key":"99558_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjad082","author":"H Yao","year":"2024","unstructured":"Yao, H., Zhang, M. & Wang, D. The next decade of SET: From an oncoprotein to beyond. J. Mol. Cell. Biol. https:\/\/doi.org\/10.1093\/jmcb\/mjad082 (2024).","journal-title":"J. Mol. Cell. Biol."},{"key":"99558_CR29","doi-asserted-by":"publisher","first-page":"14913","DOI":"10.18632\/oncotarget.3818","volume":"6","author":"H Liu","year":"2015","unstructured":"Liu, H. et al. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. Oncotarget 6, 14913\u201314925. https:\/\/doi.org\/10.18632\/oncotarget.3818 (2015).","journal-title":"Oncotarget"},{"key":"99558_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/emmm.201201283","volume":"5","author":"SA Saddoughi","year":"2013","unstructured":"Saddoughi, S. A. et al. Sphingosine analogue drug FTY720 targets I2PP2A\/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol. Med. 5, 105\u2013121. https:\/\/doi.org\/10.1002\/emmm.201201283 (2013).","journal-title":"EMBO Mol. Med."},{"key":"99558_CR31","doi-asserted-by":"publisher","first-page":"638","DOI":"10.18632\/oncotarget.6313","volume":"7","author":"MH Hung","year":"2016","unstructured":"Hung, M. H. et al. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A. Oncotarget 7, 638\u2013655. https:\/\/doi.org\/10.18632\/oncotarget.6313 (2016).","journal-title":"Oncotarget"},{"key":"99558_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1476-4598-13-32","volume":"13","author":"LM Sobral","year":"2014","unstructured":"Sobral, L. M. et al. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models. Mol. Cancer 13, 32. https:\/\/doi.org\/10.1186\/1476-4598-13-32 (2014).","journal-title":"Mol. Cancer"},{"key":"99558_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/sj.emboj.7601518","volume":"26","author":"JP ten Klooster","year":"2007","unstructured":"ten Klooster, J. P., Leeuwen, I., Scheres, N., Anthony, E. C. & Hordijk, P. L. Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J. 26, 336\u2013345. https:\/\/doi.org\/10.1038\/sj.emboj.7601518 (2007).","journal-title":"EMBO J."},{"key":"99558_CR34","doi-asserted-by":"publisher","first-page":"40169","DOI":"10.18632\/oncotarget.11174","volume":"8","author":"I Cristobal","year":"2017","unstructured":"Cristobal, I. et al. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer. Oncotarget 8, 40169\u201340180. https:\/\/doi.org\/10.18632\/oncotarget.11174 (2017).","journal-title":"Oncotarget"},{"key":"99558_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061655","author":"I Cristobal","year":"2020","unstructured":"Cristobal, I. et al. MicroRNA-199b downregulation confers resistance to 5-fluorouracil treatment and predicts poor outcome and response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12061655 (2020).","journal-title":"Cancers (Basel)"},{"key":"99558_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41419-019-1740-9","volume":"10","author":"W Peng","year":"2019","unstructured":"Peng, W. et al. LINC81507 act as a competing endogenous RNA of miR-199b-5p to facilitate NSCLC proliferation and metastasis via regulating the CAV1\/STAT3 pathway. Cell Death Dis. 10, 533. https:\/\/doi.org\/10.1038\/s41419-019-1740-9 (2019).","journal-title":"Cell Death Dis."},{"key":"99558_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13046-019-1170-7","volume":"38","author":"H Jin","year":"2019","unstructured":"Jin, H. et al. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression. J. Exp. Clin. Cancer Res. 38, 165. https:\/\/doi.org\/10.1186\/s13046-019-1170-7 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"99558_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cells11182791","author":"J Rhim","year":"2022","unstructured":"Rhim, J., Baek, W., Seo, Y. & Kim, J. H. From molecular mechanisms to therapeutics: Understanding MicroRNA-21 in cancer. Cells https:\/\/doi.org\/10.3390\/cells11182791 (2022).","journal-title":"Cells"},{"key":"99558_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.06.014","volume":"231","author":"J Zhong","year":"2019","unstructured":"Zhong, J. et al. miR-21-5p promotes lung adenocarcinoma progression partially through targeting SET\/TAF-Ialpha. Life Sci. 231, 116539. https:\/\/doi.org\/10.1016\/j.lfs.2019.06.014 (2019).","journal-title":"Life Sci."},{"key":"99558_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000445642","volume":"39","author":"X Ying","year":"2016","unstructured":"Ying, X. et al. MicroRNA-125b suppresses ovarian cancer progression via suppression of the epithelial-mesenchymal transition pathway by targeting the SET protein. Cell. Physiol. Biochem. 39, 501\u2013510. https:\/\/doi.org\/10.1159\/000445642 (2016).","journal-title":"Cell. Physiol. Biochem."},{"key":"99558_CR41","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3109\/09513590.2013.871525","volume":"30","author":"A Gadducci","year":"2014","unstructured":"Gadducci, A., Sergiampietri, C., Lanfredini, N. & Guiggi, I. Micro-RNAs and ovarian cancer: The state of art and perspectives of clinical research. Gynecol. Endocrinol. 30, 266\u2013271. https:\/\/doi.org\/10.3109\/09513590.2013.871525 (2014).","journal-title":"Gynecol. Endocrinol."},{"key":"99558_CR42","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.7754\/Clin.Lab.2016.160426","volume":"62","author":"B Zhan","year":"2016","unstructured":"Zhan, B., Lu, D., Luo, P. & Wang, B. Prognostic value of expression of MicroRNAs in non-small cell lung cancer: A systematic review and meta-analysis. Clin. Lab. 62, 2203\u20132211. https:\/\/doi.org\/10.7754\/Clin.Lab.2016.160426 (2016).","journal-title":"Clin. Lab."},{"key":"99558_CR43","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1038\/onc.2010.620","volume":"30","author":"HJ Kwak","year":"2011","unstructured":"Kwak, H. J. et al. Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene 30, 2433\u20132442. https:\/\/doi.org\/10.1038\/onc.2010.620 (2011).","journal-title":"Oncogene"},{"key":"99558_CR44","doi-asserted-by":"publisher","first-page":"9628","DOI":"10.1158\/0008-5472.CAN-05-2352","volume":"65","author":"Y Hayashita","year":"2005","unstructured":"Hayashita, Y. et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65, 9628\u20139632. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2352 (2005).","journal-title":"Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99558-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T15:56:25Z","timestamp":1746201385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99558-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["99558"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-99558-9","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20221280","asserted-by":"subject"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15441"}}